Somatic Mutation in Chronic Liver Disease
Launched by THE WELLCOME SANGER INSTITUTE · Oct 22, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pre-collected cohorts of liver tissue collected from adults (male and female) with consent and ethical approval for use in research.
- Exclusion Criteria:
- • Anything outside of the above including samples other than liver tissue, samples where there is no consent or ethical approval for use in research and/or samples from children.
About The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world-renowned genomics research center based in the UK, dedicated to advancing our understanding of human health and disease through cutting-edge genomic science. As a prominent sponsor of clinical trials, the institute leverages its expertise in genetics, bioinformatics, and large-scale data analysis to explore innovative therapeutic approaches and facilitate the translation of research findings into clinical applications. Committed to collaboration and excellence, the Wellcome Sanger Institute plays a pivotal role in the global biomedical research community, driving forward discoveries that have the potential to improve patient outcomes and transform healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Patients applied
Trial Officials
Peter Campbell
Principal Investigator
Wellcome Sanger Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported